{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Raymond+Chung",
    "query": {
      "sponsor": "Raymond Chung"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T14:47:40.954Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03026023",
      "title": "Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiac Transplant Disorder",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raymond T. Chung, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-08-01",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-09-30T14:47:40.954Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03026023"
    },
    {
      "nct_id": "NCT04343976",
      "title": "Pegylated Interferon Lambda Treatment for COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "COVID"
      ],
      "interventions": [
        {
          "name": "Pegylated interferon lambda",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raymond Chung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-06-22",
      "completion_date": "2021-07-30",
      "has_results": true,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-09-30T14:47:40.954Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04343976"
    },
    {
      "nct_id": "NCT05028829",
      "title": "Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Fibroses",
        "Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Atorvastatin 20mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raymond Chung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-05-10",
      "completion_date": "2031-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-09-30T14:47:40.954Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028829"
    },
    {
      "nct_id": "NCT03781726",
      "title": "Multi-center Study to Transplant Hepatitis-C Infected Kidneys",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Failure Chronic",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "glecaprevir/pibrentasvir treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raymond Chung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-04-10",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-09-30T14:47:40.954Z",
      "location_count": 7,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03781726"
    },
    {
      "nct_id": "NCT03623568",
      "title": "Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Failure",
        "Kidney Diseases",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "glecaprevir/pibrentasvir tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raymond T. Chung, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-02-15",
      "completion_date": "2021-04-15",
      "has_results": false,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-09-30T14:47:40.954Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03623568"
    }
  ]
}